Market cap
$9 Mln
Recently Viewed
Clear AllMarket cap
$9 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-1.9 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.3
Debt to Equity
0
Book Value
$12.1
EPS
$-14.4
Face value
--
Shares outstanding
4,161,971
CFO
£-161.70 Mln
EBITDA
£-234.03 Mln
Net Profit
£-210.20 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
NuCana - ADR
| -40.0 | 13.1 | -38.8 | -100.0 | -96.1 | -89.6 | -- |
|
BSE Sensex
| -7.8 | 4.8 | -6.3 | 3.9 | 8.9 | 10.0 | 11.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
NuCana - ADR
| -100.0 | 297.5 | -55.2 | -72.3 | -47.0 | -26.4 | -57.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs... into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. It has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom. Address: 3 Lochside Way, Edinburgh, United Kingdom, EH12 9DT Read more
Founder, CEO & Executive Director
Mr. Hugh Stephen Griffith
Founder, CEO & Executive Director
Mr. Hugh Stephen Griffith
Headquarters
Edinburgh
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of NuCana plc - ADR is $2.16 (NASDAQ) as of 15-Apr-2026 14:30 EDT. NuCana plc - ADR has given a return of -96.07% in the last 3 years.
Since, TTM earnings of NuCana plc - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.25
|
0.30
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of NuCana plc - ADR are Rs 50,000.00 and Rs 1.33 as of 16-Apr-2026.
NuCana plc - ADR has a market capitalisation of $ 9 Mln as on 14-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in NuCana plc - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.